Literature DB >> 11113678

Pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension: hemodynamic characteristics and changes.

A M D'Armini1, B Cattadori, C Monterosso, C Klersy, V Emmi, F Piovella, G Minzioni, M Viganò.   

Abstract

OBJECTIVE: To see whether degree of pulmonary hypertension or severity of cardiac failure affect the success of pulmonary thromboendarterectomy (PTE) in chronic thromboembolic pulmonary hypertension.
METHODS: From May 1996 to June 1999, 33 patients, all in New York Heart Association (NYHA) class 3 or 4 were treated with PTE. Preoperative hemodynamic values were: central venous pressure (CVP) 8+/-6 (1-23), mean pulmonary artery pressure (mPAP) 50+/-10 (30-69), cardiac output (CO) 3.3+/-0.9 (1.8-5.2), pulmonary vascular resistance (PVR) 1056+/-344 (523-1659), and right ventricle ejection fraction (RVEF) 12+/-5 (5-21). To establish whether some hemodynamic or cardiac variables correlate with surgical failure (early death or functional non-success), these patients were divided into a low risk or a high risk group for each variable: CVP (<9 or > or =9), mPAP (<50 or > or =50), CO (> or =3.5 or <3.5), PVR (> or =1100 or <1100), and RVEF (> or = 10 or <10). The duration of 3-4 NYHA class period (<24 or > or = 24 months) was also included in the study.
RESULTS: Three patients (9. 1%) died in hospital, one (3.0%) underwent lung transplant shortly after PTE, and in five cases (15.2%) mPAP and PVR at the 3-month follow-up examination corresponded with our definition of functional nonsuccess (mPAP and PVR decreased by less than 40% of preoperative values). One of the five functional nonsuccess patients underwent lung transplant 3 months after the operation and another died 17 months after the operation from a non-related cause. Thus PTE was successful in 24 patients and unsuccessful in nine. None of the hemodynamic variables considered was found to be associated with the disparate outcomes. At the 3-month examination, all surviving patients were in NYHA class 1 or 2 except for three in NYHA class 3. At 2 years, hemodynamic values were: CVP 2+/-2 (0-4), mPAP 16+/-3 (12-21), CO 5.0+/-1.0 (3.4-6.5), PVR 182+/-51 (112-282), and RVEF 35+/-5 (26-40). All differences were significant with respect to baseline values (P<0.001). Preoperative mPAP and RVEF values had a strict linear correlation (R=0.45; P=0.014).
CONCLUSIONS: None of the variables considered was correlated with early death or functional nonsuccess. Neither preoperative severity of pulmonary hypertension nor degree of cardiac failure influenced the outcome of the operation. PTE leads to hemodynamic recovery even in very compromised patients.

Entities:  

Mesh:

Year:  2000        PMID: 11113678     DOI: 10.1016/s1010-7940(00)00584-4

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  11 in total

1.  Pulmonary thromboendarterectomy almost 50 years after the first surgical attempts.

Authors:  I Cerveri; A M D'Armini; M Viganò
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

2.  Pulmonary Thromboendarterectomy for Pulmonary Hypertension Before Considering Transplant.

Authors:  Hannah Kooperkamp; Inder Mehta; David Fary; Michael Bates
Journal:  Ochsner J       Date:  2017

3.  Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report.

Authors:  Simona Roggero; Silvia Vullo; Gisella Volpe; Antonio Piga; Carlo Albera
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

4.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

5.  Perfusion techniques for pulmonary thromboendarterectomy under deep hypothermia circulatory arrest: a case series.

Authors:  Bingyang Ji; Jinping Liu; Yongbo Wu; Guyan Wang; Zhengyi Feng; Mingzheng Liu; Cun Long; Yunhu Song
Journal:  J Extra Corpor Technol       Date:  2006-12

6.  Mid term effects of pulmonary thromboendarterectomy on clinical and cardiopulmonary function status.

Authors:  M C Zoia; A M D'Armini; M Beccaria; A Corsico; P Fulgoni; C Klersy; F Piovella; M Viganò; I Cerveri
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

7.  Calpain inhibition attenuates right ventricular contractile dysfunction after acute pressure overload.

Authors:  Clifford R Greyson; Gregory G Schwartz; Li Lu; Shuyu Ye; Steve Helmke; Ya Xu; Hasan Ahmad
Journal:  J Mol Cell Cardiol       Date:  2007-10-23       Impact factor: 5.000

8.  High preoperative plasma endothelin-1 levels are associated with increased acute kidney injury risk after pulmonary endarterectomy.

Authors:  Fabrizio Grosjean; Mara De Amici; Catherine Klersy; Gianluca Marchi; Antonio Sciortino; Federica Spaltini; Maurizio Pin; Valentina Grazioli; Anna Celentano; Benedetta Vanini; Giorgia Testa; Vincenzo Sepe; Teresa Rampino; Andrea Maria D'Armini
Journal:  J Nephrol       Date:  2018-09-18       Impact factor: 3.902

9.  Non-invasive evaluation of hemodynamics in pulmonary hypertension by a Septal angle measured by computed tomography pulmonary angiography: Comparison with right-heart catheterization and association with N-terminal pro-B-type natriuretic peptide.

Authors:  Qiang Tang; Min Liu; Zhanhong Ma; Xiaojuan Guo; Tuguang Kuang; Yuanhua Yang
Journal:  Exp Ther Med       Date:  2013-09-30       Impact factor: 2.447

10.  Clinical outcomes of thromboendarterectomy for chronic thromboembolic pulmonary hypertension: 12-year experience.

Authors:  Se Jin Oh; Jin San Bok; Ho Young Hwang; Kyung-Hwan Kim; Ki Bong Kim; Hyuk Ahn
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.